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comptroller general of the GAO, 
as long as dialysis facilities “re-
ceive a separate payment for each 
administration of each [separate-
ly billable] drug and the payment 
exceeds the costs of acquiring 
the drug, an incentive remains 
to use more of these drugs than 
necessary.”
Under its monitoring policy, 
Medicare expects that providers, 
in addition to following the FDA 
label instructions for epoetin, will 
reduce the dose by 25% if the 
patient’s hematocrit exceeds 39.0 
(a hemoglobin level of 13.0 g 
per deciliter). Even if the dose is 
not reduced, CMS decreases the 
payment. This payment-reduction 
threshold recognizes clinical vari-
ability in maintaining hemoglobin 
levels in individual patients. None-
theless, the House Committee on 
Ways and Means and others have 
criticized the CMS policy because 
the level that triggers a reduction 
in payment is higher than the 
FDA’s maximum target level for 
patient care.
Medicare uses a bundled-pay-
ment approach to pay for most 
services. According to the GAO, 
extending this approach to all 
ESRD services would make treat-
ment choices “payment neutral” 
and encourage “providers to op-
erate efficiently, as they retain 
the difference if Medicare’s pay-
ment exceeds the costs they in-
cur to provide the services.”1 For 
example, providers might admin-
ister epoetin to more patients 
subcutaneously, which requires 
considerably less drug than intra-
venous administration to achieve 
the same effect. Of course, the 
success of a global, prospective-
ly set rate depends on the design 
of the implementation strategy. 
In addition to avoiding incentives 
for undertreating, critical issues 
include the reimbursement rate, 
how it is updated to reflect chang-
es in costs and medical practice, 
and how Medicare adjusts pay-
ments to account for the distri-
bution among centers of patients 
whose care is more or less ex-
pensive. Moreover, in the case of 
epoetin, other approaches to cost 
reduction could complement ef-
forts to control utilization. Exam-
ples include a lower reimburse-
ment rate, price competition with 
other medications, and legisla-
tion to provide Medicare with the 
authority to negotiate lower drug 
prices.
Under the Medicare Prescrip-
tion Drug, Improvement, and Mod-
ernization Act of 2003, Congress 
required CMS to submit, in Oc-
tober 2005, a report on how a 
bundled-payment system for ESRD 
would be designed and to start a 
3-year bundling demonstration in 
January 2006.1 In her testimony 
at the December hearings, Leslie 
Norwalk, the acting CMS admin-
istrator, said that the agency gen-
erally supports shifting to such 
a system but wants to finalize 
the details first. The CMS report, 
however, has yet to be submitted, 
and the demonstration project has 
not started. Congress will have to 
decide whether to wait at least sev-
eral more years for the results or 
to create a bundled-payment sys-
tem before they become available.
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Related articles, pages 29 and 39
In 1997, Connolly et al. reported that both racemic fenfluramine 
(Pondimin) and dexfenfluramine 
(Redux) were associated with val-
vular heart disease.1 The valvular 
abnormalities seen in patients 
treated with these agents were 
distinctive. On echocardiography, 
leaflet thickening as well as chord-
al thickening and retraction were 
observed. Surgically removed valves 
were noted to have a glistening 
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white surface, with histologic evi-
dence of a plaque-like process ex-
tending along the leaflet surfaces 
and encasing the chordae tendin-
eae. These findings were similar 
to those in patients with heart-
valve damage induced by seroto-
nin-secreting carcinoid tumors.1
This association of racemic 
fenfluramine and dexfenfluramine 
with valvular heart disease led 
to the withdrawal of both drugs 
from the market. Because of the 
observed similarity to carcinoid 
heart disease, and because fen-
f luramine and its active metabo-
lite norfenfluramine are agonists 
at various serotonin (5-hydroxy-
tryptamine, or 5-HT) receptors, 
Devereux urged caution “in the 
long-term use of other agents 
that act on serotonergic mecha-
nisms.” 2 Since a large number of 
commonly prescribed medica-
tions, including antidepressant, 
antipsychotic, anxiolytic, antimi-
graine, and other drugs, have se-
rotonergic mechanisms, there was 
concern that numerous approved 
drugs might also cause valvular 
heart disease.2
In 2000, we and others re-
ported that norfenfluramine is a 
potent agonist at 5-HT2B recep-
tors.3 These receptors are plenti-
ful in human cardiac valves and 
appear to be essential for normal 
cardiac development. In contrast, 
norfenfluramine is devoid of ap-
preciable activity at many other 
types of receptors that are plen-
tiful in the heart, including all 
known biogenic amine (e.g., α1-, 
α2-, and β-adrenergic) receptors 
and peptide receptors.3 In sub-
sequent studies, we found that 
ergotamine, an ergot derivative 
that has also been reported to 
induce valvular heart disease, 
activates 5-HT2B receptors and that 
methylergonovine, the active me-
tabolite of the prototypic valvu-
lopathic agent methysergide, is 
an extraordinarily potent 5-HT2B 
agonist.4 Taken together, these 
findings implicated activation of 
5-HT2B receptors as a key step in 
initiating drug-induced valvular 
heart disease.
Valvulopathic drugs have been 
shown to induce mitogenesis in 
cultured interstitial cells from hu-
man cardiac valves by activating 
the 5-HT2B receptor.4 My research 
group has suggested that valvu-
lopathy induced by 5-HT2B recep-
tors is caused by the inappropriate 
mitogenic stimulation of normally 
quiescent valve cells, resulting in 
an overgrowth valvulopathy (see 
diagram).4 Although the precise 
signaling pathways leading to 
valvulopathy are unknown, 5-HT2B 
receptors are known to activate 
mitogenic pathways through the 
phosphorylation of Src kinase and 
extracellular regulated kinases 
(ERK). Both classic G-protein–
mediated signaling pathways and 
new pathways involving arrestin 
and other accessory proteins may 
be involved in activating the mi-
togenic pathways; it is also likely 
that cross talk with receptor ty-
rosine kinases is important for 
mitogenesis (see diagram).5
It was subsequently discovered 
that two antiparkinsonian dopa-
mine agonists, pergolide and ca-
bergoline, are potent 5-HT2B ago-
nists; they were therefore predicted 
to be valvulopathic agents.5 Other 
commonly prescribed antiparkin-
sonian drugs such as apomor-
phine, pramipexole, bromocrip-
tine, lisuride, and roxindole are 
devoid of 5-HT2B–agonist activity 
and, accordingly, were not expect-
ed to induce valvular regurgita-
tion. As predicted, case reports of 
cabergoline- and pergolide-induced 
valvular heart disease soon ap-
peared.
In this issue of the Journal, two 
large European studies indepen-
dently verify the association of 
valvular heart disease with per-
golide and cabergoline. Schade 
et al. (pages 29–38) conducted a 
population-based study to inves-
tigate the associations between 
six dopamine agonists (bromo-
criptine, cabergoline, pergolide, 
lisuride, pramipexole, and ropin-
irole) and valvular heart disease. 
Only pergolide and cabergoline 
— the only two dopamine ago-
nists that are also potent 5-HT2B 
agonists — were significantly as-
sociated with cardiac-valve disease. 
Mitral, aortic, and tricuspid valves 
were affected. Lisuride, which is 
an agonist at two related seroto-
nin receptors (5-HT2A and 5-HT2C) 
but is not a 5-HT2B agonist, was 
not associated with valve disease. 
The findings concerning lisuride 
further implicate 5-HT2B seroto-
nin–receptor activation as a key 
step in the progression of drug-
induced valvulopathy. Schade et 
al. also report that amantadine 
is associated with an increased 
risk of valvular heart disease. It 
will be important to determine 
whether amantadine (or one of its 
metabolites) also activates 5-HT2B 
receptors.
In the second study, Zanettini 
et al. (pages 39–46) found that 
clinically significant regurgita-
tion was discovered only in pa-
tients taking pergolide or caber-
goline. The rates of drug-induced 
valvulopathy were high (23.4% 
and 28.6% in the pergolide and 
cabergoline groups, respectively, 
vs. 5.6% among controls) but were 
similar to those reported previ-
ously in a smaller study. In the 
Zanettini study, as in the study by 
Schade et al., drug-induced insuf-
ficiency was evident in mitral, aor-
tic, and tricuspid valves.
These two studies reinforce the 
notion of a causal association be-
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tween 5-HT2B agonism and val-
vular heart disease. Such an as-
sociation has now been seen with 
drugs for diverse indications, in-
cluding anorectic agents (fenflur-
amine), antimigraine drugs (di-
hydroergotamine, methysergide, 
and ergotamine), and antiparkin-
sonian agents (pergolide and ca-
bergoline). On the basis of these 
findings, my colleagues and I have 
urged pharmaceutical companies 
and regulatory agencies to screen 
candidate drugs and their major 
metabolites at 5-HT2B receptors 
comprehensively before launching 
clinical trials, in order to pre-
vent “fen–phen”-type disasters.3,5 
Clearly, practitioners should avoid 
prescribing drugs that are potent 
5-HT2B–receptor agonists — a 
growing list of medications that 
now includes ergot derivatives (er-
gotamine, methysergide, and di-
hydroergotamine), dopamine ago-
nists (pergolide and cabergoline), 
and amphetamine derivatives (fen-
fluramine and methylenedioxy-
methamphetamine [MDMA, or 
“ecstasy”]).
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Molecular Mechanisms by Which 5-HT2B Agonists 
Induce Valvular Heart Disease.
Both prescribed drugs (such as pergolide, cabergo-
line, and ergotamine) and their active metabolites 
(such as norfenfluramine and methylergonovine) 
activate 5-HT2B receptors, a subtype of serotonin 
receptors. Chemically similar medications that do 
not activate 5-HT2B receptors (e.g., lisuride) do 
not cause valvular heart disease, further implicat-
ing this receptor in the pathogenesis of heart-valve 
disease. Activation of 5-HT2B receptors leads to 
the dissociation of the heterotrimeric G protein, 
liberating the Gαq subunit, which in turn activates 
phospho lipase C-β (PLC-β). Activation of PLC-β 
leads to the activation of protein kinase C (PKC) 
through the mobilization of intracellular calcium 
and the liberation of diacylglycerol (DAG). Although 
all the specifics are not yet known, G proteins may 
also induce Src phosphorylation (forming Src-P) 
and activation, as well as the activation of the path-
ways of extracellular regulated kinases (ERK). In 
addition, Src-P may both mediate and enhance 
the activity of the transforming growth factor β 
(TGF-β) receptor, augmenting 5-HT2B–stimulated 
mitogenesis. For many G-protein–coupled recep-
tors, the binding of β-arrestin (βArr) may facilitate 
activation of ERK1 and ERK2. The final common 
pathway by which activation of 5-HT2B receptors 
leads to mitogenesis probably involves the phos-
phorylation of retinoblastoma protein (Rb-P). 
Excessive cell division leads to an overgrowth val-
vulopathy and subsequent valvular dysfunction.
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